Pharsight

Lexiscan patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6403567 ASTELLAS N-pyrazole A2A adenosine receptor agonists
Apr, 2022

(1 year, 5 months ago)

US8106183 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47301 ASTELLAS Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Feb, 2027

(3 years from now)

Lexiscan is owned by Astellas.

Lexiscan contains Regadenoson.

Lexiscan has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Lexiscan are:

  • US6403567

Lexiscan was authorised for market use on 10 April, 2008.

Lexiscan is available in solution;intravenous dosage forms.

Lexiscan can be used as method for stimulating coronary vasodilation for purposes of imaging the heart.

The generics of Lexiscan are possible to be released after 02 February, 2027.

Drugs and Companies using REGADENOSON ingredient

Market Authorisation Date: 10 April, 2008

Treatment: Method for stimulating coronary vasodilation for purposes of imaging the heart

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of LEXISCAN before it's drug patent expiration?
More Information on Dosage

LEXISCAN family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic